摘要
目的 观察MEAD化疗方案治疗难治复发性成年人急性淋巴细胞白血病(ALL)的疗效和安全性.方法 对2006年6月至2009年6月收治的22例成年人难治复发性ALL患者,采用MEAD方案化疗,米托蒽醌6 mg/d静脉滴注,第1天至第3天;阿糖胞苷100 mg/d静脉滴注,第1天至第5天;依托泊苷100mg/d静脉滴注,第1天至第5天;地塞米松10mg/d静脉滴注,第1天至第8天.结果 成年人难治复发性ALL完全缓解率31.8%.部分缓解率22.7%,总有效率54.5%;两次MEAD方案化疗后,累积完全缓解率为50.0%,部分缓解率40.9%.主要不良反应为不同程度的骨髓抑制,重要脏器毒性反应轻微.结论 MEAD化疗方案对难治复发性成年人ALL有较好的疗效.患者不良反应轻微.
Objective To study the clinic effect and safety of MEAD chemotherapy regimen for adult patients with relapsed or refractory acute lymphocyte leukemia. Methods Between July 2006 and July 2009,twenty-two adult patients with relapsed or refractory acute lymphocyte leukemia received MEAD regimen (mitoxantrone 6 mg/d dl-3 iv drip,cytarabine 100 mg/d dl-5 iv drip,etoposide 100 mg/d dl-5 iv drip,dexmethasone 10 mg/d dl-8 iv drip). Results The complete remission (CR) rate of adult patients with relapsed or refractory acute lymphocyte leukemia was 31.8 %,the partial remission(PR) rate was 22.7 % and the overall response (OR) rate 54.5 %. The cumulitive CR rate was 50.0 %,and the PR rate 40.9 % after two times MEAD chemotherapy regimen. The main adverse effect was different level of myelosuppression,and other toxicity of vital organ was mild. Conclusion MEAD regimen is effective and can be tolerated for adult patients with relapsed or refractory acute lymphocyte leukemia,and its side effect is mild.
出处
《白血病.淋巴瘤》
CAS
2010年第6期349-351,共3页
Journal of Leukemia & Lymphoma
关键词
白血病
淋巴细胞
急性
成年人
抗肿瘤联合化疗方案
Leukemia,lymphocytic,acute
Adult
Antineoplastic combined chemotherapy protocols